CAVE (Cetuximab-AVElumab) mCRC: A Single Arm Phase II Clinical Study of the Combination of Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer Patients
Latest Information Update: 28 Feb 2023
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms CAVE mCRC
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium
- 01 Aug 2022 Results published in the International Journal of Cancer
- 04 May 2022 Status changed from active, no longer recruiting to completed.